Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin cancer treatments.

By blocking the newly identified site, these TLR8 inhibitors appear to antagonize the binding of TLR8 agonists such as R848 and uridine, and/or block a conformational change necessary for the receptor activation.

TLR8 is an endosomal receptor that recognizes single stranded RNA (ssRNA), and can recognize ssRNA viruses such as Influenza, Sendai, and Coxsackie B viruses.

Feb 1, 2005 · In this study TLR agonists selective for TLR7 or TLR8 were used to determine the repertoire of human innate immune cells that are activated through these TLRs. We found that TLR7 agonists directly activated purified plasmacytoid dendritic …

Aug 1, 2021 · Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin cancer treatments.

JNJ-64794964 (JNJ-4964/AL-034/TQ-A3334), an oral toll-like receptor 7 agonist, is being investigated for the treatment of chronic hepatitis B (CHB), a condition with a high unmet medical need.

Mar 14, 2025 · R848 is a synthetic agonist that activates Toll-like receptors 7 and 8 (TLR7/8), key components of the innate immune system. By stimulating these receptors, R848 initiates …

Jul 3, 2018 · TLR7-specific agonists activate pDCs and induce mainly IRF7-driven signaling, IFN-α, and IFN-regulated cytokines. TLR8-specific agonists activate monocytes and myeloid DCs, leading primarily to the NF-κB activation and production of proinflammatory cytokines and chemokines, such as IL-12p70.

To definitively confirm that TLR8 is responsible of the functionally activation of NK cells when triggered by TLR8 agonist, we performed the TLR8 genetic silencing of resting NK cells by siRNA transfection.

Dec 1, 2021 · JNJ-64794964 (JNJ-4964/AL-034/TQ-A3334), an oral toll-like receptor 7 agonist, is being investigated for the treatment of chronic hepatitis B (CHB), a condition with a high unmet medical need.